- Shire (NASDAQ:SHPG) has agreed to pay a $350M settlement over U.S. claims that it used "kickbacks and other unlawful methods" to induce doctors to prescribe Dermagraft, a bioengineered human skin substitute.
- Deputy U.S. attorney-general Benjamin Mizer, head of the DOJ's civil division, said the settlement was "the largest False Claims Act recovery" in a kickback case involving a medical product.